CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers & Opportunities
4.1.1. Rising demand for minimally invasive procedures
4.1.2. Technological advancements in embolic protection devices
4.1.3. Rising incidence of cardiovascular & neurovascular diseases
4.1.4. Funding and investments for R&D on embolic protection devices
4.1.5. Growth opportunities in emerging markets
4.2. Market Restraints & Challenges
4.2.1. Lack of skilled professionals
4.2.2. Product failure and recalls
4.2.3. Stringent regulatory scenario and unfavourable government policies
CHAPTER 5. GLOBAL EMBOLIC PROTECTION DEVICES MARKET – BY TYPE &
MATERIAL
5.1. Type
5.1.1. Proximal Occlusion Devices
5.1.2. Distal Occlusion Devices
5.1.3. Distal Filter Devices
5.2. Material
5.2.1. Polyurethane
5.2.2. Nitinol
CHAPTER 6. GLOBAL EMBOLIC PROTECTION DEVICES MARKET – BY
INDICATION
6.1. Saphenous Vein Graft Disease
6.2. Transcather Aortic Valve Replacement
6.3. Percutaneous Coronary Intervention
6.4. Carotid Artery Diseases
6.5. Others
CHAPTER 7. GLOBAL EMBOLIC PROTECTION DEVICES MARKET - BY
APPLICATION
7.1. Neurovascular Diseases
7.2. Peripheral Vascular Diseases
7.3. Cardiovascular Diseases
7.4. Others
CHAPTER 8. GLOBAL EMBOLIC PROTECTION DEVICES MARKET – BY END
USER
8.1. Ambulatory Surgical Centers
8.2. Hospitals
8.3. Others
CHAPTER 9. GLOBAL EMBOLIC PROTECTION DEVICES MARKET - BY
GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
8.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL EMBOLIC PROTECTION DEVICES MARKET - COMPANY
PROFILES
10.1. Cardinal Health, Inc.
10.2. Abbott Laboratories, Pvt. Ltd.
10.3. Medtronic PLC
10.4. W. L. Gore & Associates, Inc.
10.5. Boston Scientific Corporation
10.6. Saphena Medical, Inc.
10.7. Innovative Cardiovascular Solutions, LLC.
10.8. Metactive Medical, LLC.
10.9. Contego Medical, LLC.
10.10. Edward Lifesciences Corp.
10.11. Silk Road Medical, Inc.
CHAPTER 11. GLOBAL EMBOLIC PROTECTION DEVICES MARKET –
COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
